FDA Statement regarding azithromycin (Zithromax) and the risk of cardiovascular death – Center for Food Safety and Applied Nutrition

The risks of cardiovascular death associated with levofloxacin treatment were similar to those associated with azithromycin treatment. FDA is reviewing the results from this study and will communicate any new information that results from the FDA review.